Maryland Technology Internship Program

The Wisconsin Economic Development Corporation is partnering to offer Entrepreneurial Training Program reimbursement of up to 75% of the $1,000 course fee. The course is designed to help early-stage startups vet their ideas and learn how to develop an investment-ready business plan. Grant recipients must comply with requirements that include meeting attendance standards and completing a business plan within six months of starting the program.

The FoundHer accelerator program focuses on Hawaii-based women entrepreneurs. Accepted participants to the six-month program will receive $20,000 grants, a $4,000 care stipend, weekly educational workshops, and monthly learning and networking retreats. Businesses must be early-stage, for-profit and at least 51% Asian American, Native Hawaiian and Pacific Islander-owned to qualify.

This FOA encourages research relevant to the development of novel screening approaches and/or therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as for "high priority" genetic conditions where screening may be possible in the near future.Having an accurate screening test, as well as demonstrating the benefits of early intervention or treatment, are important criteria for including a condition on a newborn screening panel. This FOA defines a "high priority" condition as one where screening is not currently recommended, but infants with the condition would significantly benefit from early identification and treatment.

The San Francisco Environment Department is offering grants of up to $2,500 to help food service businesses lease or purchase an automatic dishwasher, cover minor installation costs, and buy essential dishwashing supplies. The purpose of this grant is to help San Francisco food service businesses reduce waste by building or expanding their reusable foodware use and systems for on-site dining. Funding is specifically intended to support businesses in transitioning from disposable foodware and to long-term reuse solutions, in alignment with San Francisco’s zero waste goals. Grants are available only until funding runs out. Early applications are strongly encouraged.

This Notice of Funding Opportunity (NOFO) encourages applications for investigator-initiated, early phase, clinical trials of natural products (i.e., botanicals, dietary supplements, and probiotics), which have a strong scientific premise to justify further clinical testing. For this NOFO, natural products include promising nutritional regimens that standardize the amount of a specific naturally occurring nutritional compound (e.g., omega-3 fatty acids, anthocyanidins, or polyphenols) and have compelling preliminary evidence. Under this NOFO, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support decisions about further development or testing of the natural product. This NOFO will provide up to 3 years support for studies to replicate the impact of the natural product on target engagement when used by humans, and assess whether there is an association between the degree of the impact on target engagement and functional or clinical outcomes in a patient population. Applications are encouraged to design studies to determine how to optimize the impact of the natural product on target engagement by optimizing the delivery of the natural product through examination of different doses or formulations. In addition, applications can be designed to combine the natural product with another treatment approach that is known to engage the same target; or study the impact of the natural product in a target population that is more responsive. Clinical trials submitted under this NOFO are expected to be hypothesis based, milestone-driven, and directly related to the research priorities and mission of NCCIH. This R33 funding mechanism is intended to accelerate the translation of emerging basic science findings about natural products into early-stage clinical testing to determine whether continued clinical research is warranted. This NOFO will not support efficacy or effectiveness trials, nor will